Clinical Trial Update: Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating pembrolizumab plus olaparib in recurrent cervical cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Saitama Medical University International Medical Center | Conditions: Cervical Cancer | Phase 2 | Status: UNKNOWN